CLAIMS

1. An anilide derivative, characterized in that it corresponds to general formula I:

5

in which:

15

10

- R₁ represents a hydroxyl or amino group,
- R₂ represents hydrogen or a methyl radical,
- R₃ represents hydrogen or a fluorine atom,
- A represents a group

20

in which:

- 25 n represents an integer from 5 to 11, limits inclusive,
 - R_4 and R_5 , which may be identical or different, represent, independently of one another, hydrogen or a fluorine atom

30

in which n, R_4 and R_5 have the same meaning as above,

in the form of their various stereoisomers and enantiomers, and mixtures thereof, for the compounds having one or more asymmetric carbons, and in the form

of therapeutically acceptable inorganic or organic acid salts for the salifiable compounds.

- 2. A compound corresponding to general formula I as claimed in claim 1, selected from the following group:
- (S)-2',3',5'-trimethyl-4'-hydroxy- α -dodecylsulfonyl- α -phenylacetanilide
- (S)-2',3',5'-trimethyl-4'-hydroxy- α -(12,12-difluoro-dodecylsulfonyl)- α -phenylacetanilide
- 10 2',3',5'-trimethyl-4'-hydroxy- α -dodecylsulfonyl- α -fluoro- α -phenylacetanilide
 - 2',3',5'-trimethyl-4'-hydroxy- α -(2-dodecyl-2H-5-tetrazolyl)- α -phenylacetanilide
 - (+)-2',3',5'-trimethyl-4'-hydroxy- α -(2-dodecyl-2H-5-
- 15 tetrazolyl) $-\alpha$ -phenylacetanilide

5

30

35

- (+)-2',3',5'-trimethyl-4'-hydroxy- α -(2-hexyl-2H-5-tetrazolyl)- α -phenylacetanilide
- 2',3',5'-trimethyl-4'-hydroxy- α -(2-decyl-2H-tetrazolyl)- α -phenylacetanilide
- 20 2',3',5'-trimethyl-4'-hydroxy- α -[(2-(6,6-difluoro-hexyl)-2H-tetrazolyl]- α -phenylacetanilide
 - (+)-2',3',5'-trimethyl-4'-hydroxy- α -(2-dodecyl-2H-5-tetrazolyl)- α -fluoro- α -phenylacetanilide
 - 2',3',5'-trimethyl-4'-hydroxy- α -[2-(12,12-difluorododecyl)-2H-5-tetrazolyl]- α -fluoro- α -phenylacetanilide
- 25 dodecyl)-2H-5-tetrazolyl]- α -fluoro- α -phenylacetanilide - 2',3',5',6'-tetramethyl-4'-amino- α -(2-dodecyl-2H-5-tetrazolyl)- α -fluoro- α -phenylacetanilide hydrochloride
 - 2',3',5',6'-tetramethyl-4'-amino- α -(2-hexyl-2H-5-tetrazolyl)- α -phenylacetanilide hydrochloride.
 - 3. As a medicinal product, a compound of general formula I as claimed in either of claims 1 and 2, in particular as a medicinal product that is useful in the treatment of diseases such as hypercholesterolemia or atherosclerosis.
 - 4. A pharmaceutical composition, characterized in that it contains, besides a pharmaceutically acceptable

carrier, at least one compound of general formula I as claimed in either of claims 1 and 2.

5. The use of compounds of formula I, as claimed in either of claims 1 and 2, for producing medicinal products intended for the treatment of diseases such as hypocholesterolemia or atherosclerosis.